OptimizeRx Corporation Common Stock (OPRX)

FairStock Score: 57/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at OptimizeRx as a small healthcare technology company selling digital messaging and audience tools. The turnaround label is accurate on the filed numbers: FY2023 revenue $71.5M and net loss $17.6M; FY2024 revenue $92.1M and net loss $20.1M; FY2025 revenue $109.4M and net income $5.1M, or EPS $0.27. That is real progress, but it is not yet durable. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $20.5M and net loss $703,000, versus revenue $29.2M and net income $1.5M in fiscal Q2 2025. The moat is questionable for a 132-employee health information services firm; low returns support that view. FairStock calculations at the 2026-10-13 close show P/E 33.72, P/B 1.21, ROE 3.67%, ROCE 4.22%, D/E 0.15, and FCF yield 11.7%. The Graham Number is $6.26, so the price carries a -34.66% margin of safety. Free cash flow of $18.5M is a genuine strength, and EV/EBITDA 9.79 is not demanding, but Piotroski 6/9 and Altman Z-Score 2.63 are middling. I want consistent earning power and a clearer competitive advantage before calling this a bargain. At $8.43, the market is paying for a recovery that the last two quarters have not yet confirmed. The latest quarter says the turnaround has stumbled, and without a margin of safety the stock is speculative.

In plain English: OptimizeRx sells digital messaging and data tools to healthcare and drug companies. The business has swung between losses and profits, and sales fell in the latest quarter, so it looks weak right now. At $8.43, the price looks somewhat high compared with its recent earnings, but not far from the value of its net assets.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer